Short Interest in Asterias Biotherapeutics Inc (AST) Expands By 0.6%

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) was the recipient of a significant increase in short interest during the month of September. As of September 14th, there was short interest totalling 3,611,388 shares, an increase of 0.6% from the August 31st total of 3,591,039 shares. Currently, 10.9% of the company’s stock are short sold. Based on an average daily volume of 155,582 shares, the days-to-cover ratio is presently 23.2 days.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. LMR Partners LLP acquired a new position in shares of Asterias Biotherapeutics in the second quarter valued at approximately $110,000. Creative Planning increased its holdings in shares of Asterias Biotherapeutics by 50.0% in the second quarter. Creative Planning now owns 180,313 shares of the biotechnology company’s stock valued at $243,000 after purchasing an additional 60,100 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Asterias Biotherapeutics in the second quarter valued at approximately $142,000. Millennium Management LLC acquired a new position in shares of Asterias Biotherapeutics in the second quarter valued at approximately $663,000. Finally, Paloma Partners Management Co acquired a new position in shares of Asterias Biotherapeutics in the second quarter valued at approximately $194,000.

Shares of NYSEAMERICAN AST opened at $1.35 on Wednesday. Asterias Biotherapeutics has a twelve month low of $1.20 and a twelve month high of $3.74.

Asterias Biotherapeutics (NYSEAMERICAN:AST) last issued its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.10) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.10). Asterias Biotherapeutics had a negative return on equity of 79.80% and a negative net margin of 403.38%. The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.11 million.

A number of equities research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Asterias Biotherapeutics in a research note on Tuesday, June 19th. Zacks Investment Research upgraded Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research note on Tuesday, July 10th. Raymond James cut Asterias Biotherapeutics from an “outperform” rating to a “market perform” rating in a research note on Friday, August 10th. Finally, B. Riley set a $6.00 price objective on Asterias Biotherapeutics and gave the company a “buy” rating in a research note on Friday, August 3rd.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia.

Further Reading: Market Capitalization

Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply